Beamion™ 44: Phase IIa trial of zongertinib plus platinum-based doublet chemotherapy with or without pembrolizumab in treatment-naïve patients with HER2-mutant NSCLC (NCT07486817)

Beamion™ 44: A randomized, open-label, multi-center, Phase IIa platform trial to evaluate the safety and tolerability of zongertinib plus platinum-based doublet chemotherapy with or without pembrolizumab (and potential other combinations) in treatment-naïve patients with locally advanced/metastatic non-squamous NSCLC with activating HER2 mutations¹

CNS, central nervous system; DoR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; HER2, human epidermal growth factor receptor 2; NSCLC, non-small cell lung cancer; OR, objective response; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumours; ToT, time on treatment; TRAE, treatment-related adverse event.